Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...
The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...
The primary primary cancer – which had already spread throughout her skeleton and also to her brain – was later revealed to ...
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising driver of the disease and other risk factors.
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...
21h
The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Kiromic BioPharma (KRBP) reported continued efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its ...
The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...
San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback